JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 103 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $46 | -99.9% | 25,000 | +25.0% | 0.00% | 0.0% |
| Q3 2022 | $47,000 | -23.0% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $61,000 | -55.1% | 20,000 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $136,000 | -18.6% | 20,000 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $167,000 | +125.7% | 20,000 | +100.0% | 0.00% | +200.0% |
| Q3 2021 | $74,000 | -71.0% | 10,000 | 0.0% | 0.00% | -80.0% |
| Q2 2021 | $255,000 | +147.6% | 10,000 | 0.0% | 0.01% | +150.0% |
| Q1 2021 | $103,000 | +47.1% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $70,000 | -14.6% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $82,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $20,045,000 | 88.84% |
| TRV GP III, LLC | 3,048,780 | $22,652,000 | 4.30% |
| Logos Global Management LP | 2,000,000 | $14,860,000 | 1.07% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,559 | $1,550,000 | 0.88% |
| PFM Health Sciences, LP | 3,848,822 | $28,597,000 | 0.84% |
| Yorktown Management & Research Co Inc | 113,200 | $841,000 | 0.63% |
| Moloney Securities Asset Management, LLC | 282,250 | $2,097,000 | 0.38% |
| PATHWAY CAPITAL MANAGEMENT, LP | 84,763 | $630,000 | 0.30% |
| Sofinnova Investments, Inc. | 637,347 | $4,735,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $2,047,000 | 0.23% |